Wardman M, Chintakayala P, Heywood C. The valuation and demand impacts of the worthwhile use of travel time with specific reference to the digital revolution and endogeneity. Transportation. 2019 Oct 23;47:1515-40. doi: 10.1007/s11116-019-10059-x
Batley R, Bates J, Bliemer M, Borjesson M, Bourdon J, Cabral MO, Chintakayala P, Choudhury C, Daly A, Dekker T, Drivyla E, Fowkes T, Hess S, Heywood C, Johnson D, Laird J, Mackie P, Parkin J, Sanders S, Sheldon R, Wardman M, Worsley T. New appraisal values of travel time saving and reliability in Great Britain. Transportation. 2019 Jun;46:583-621. doi: 10.1007/s11116-017-9798-7
Layton JB, Li D, Meier CR, Sharpless JL, Sturmer T, Brookhart MA. Injection testosterone and adverse cardiovascular events: a case-crossover analysis. Clin Endocrinol (Oxf). 2018 May;88(5):719-27. doi: 10.1111/cen.13574
Bristow AL, Wardman M, Chintakayala VPK. International meta-analysis of stated preference studies of transportation noise nuisance. Transportation. 2015;42:71-100. doi: 10.1007/s11116-014-9527-4
Farreny A, Aguado J, Ochoa S, Haro JM, Usall J. The role of negative symptoms in the context of cognitive remediation for schizophrenia. Schizophr Res. 2013 Oct;150(1):58-63.
Farreny A, Aguado J, Ochoa S, Huerta-Ramos E, Marsà F, López-Carrilero R, Carral V, Haro JM, Usall J. REPYFLEC cognitive remediation group training in schizophrenia: looking for an integrative approach. Schizophr Res. 2012 Dec;142(1-3):137-44. doi: 10.1016/j.schres.2012.08.035.
Graham CN, Mauskopf J, Lawson AH, Ascher-Svanum H, Bruhn D, Watson PR. Validating an industry-sponsored model comparing the cost-effectiveness of atypical antipsychotics in the treatment of schizophrenia. Schizophr Res. 2010 Apr 1;117(2-3):398-9.
Alvarez-Pedrerol M, Ribas-Fito N, Garcia-Esteban R, Rodriguez A, Soriano D, Guxens M, Mendez M, Sunyer J. Iodine sources and iodine levels in pregnant women from an area without known iodine deficiency. Clin Endocrinol (Oxf). 2010 Jan;72(1):81-6. doi: 10.1111/j.1365-2265.2009.03588.x
McDonald R, Mead N, Cheraghi-Sohi S, Bower P, Whalley D. Governing the ethical consumer: identity, choice and the primary care medical encounter. Sociol Health Illn. 2007 Apr 1;29(3):430-56.
Wirén L, Whalley D, McKenna SP, Wilhelmsen L. Application of a disease-specific, quality-of-life measure (QoL-AGHDA) in growth hormone-deficient adults and a random population sample in Sweden: validation of the measure by Rasch analysis. Clin Endocrinol (Oxf). 2000 Feb;52(2):143-52.
McKenna S, Doward LC. Measuring quality of life in adults with growth hormone deficiency. Clin Endocrinol (Oxf). 1996 Oct;45(4):507-8.